Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci

Triclocarban is an antiseptic of the anilide family. Its antibacterial activity was re-assessed in vitro against various susceptible and antibiotic resistant staphylococcus, streptococcus, and enterococcus strains. The results of this study show that, in vitro, the effectiveness of triclocarban anti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Médecine et maladies infectieuses 2012-06, Vol.42 (6), p.276-279
Hauptverfasser:	Drugeon, H-B, Rouveix, B, Michaud-Nerard, A
Format:	Artikel
Sprache:	fre
Schlagworte:	Anti-Infective Agents, Local - pharmacology Carbanilides - pharmacology Drug Resistance, Bacterial Enterococcus - drug effects Microbial Sensitivity Tests Staphylococcus - drug effects Streptococcus - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	279
container_issue	6
container_start_page	276
container_title	Médecine et maladies infectieuses
container_volume	42
creator	Drugeon, H-B Rouveix, B Michaud-Nerard, A
description	Triclocarban is an antiseptic of the anilide family. Its antibacterial activity was re-assessed in vitro against various susceptible and antibiotic resistant staphylococcus, streptococcus, and enterococcus strains. The results of this study show that, in vitro, the effectiveness of triclocarban antibacterial is maintained at very low MICs ranging from 0.5 to 8 mg/L for the various resistant strains studied. Triclocarban remains still very effective for the treatment of either initially bacterial skin and mucosal infections, or skin and mucosal at risk of super infection.
doi_str_mv	10.1016/j.medmal.2012.04.004
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023295212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1023295212</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-9d857ddde0bbe6f6144dde407109066fb8dc3f6311f363c25a785a98740ed3d13</originalsourceid><addsrcrecordid>eNo1UEtLxDAQDoK46-o_EOnRg60zSZq2R1l8wYKX9SglTVLM0pdJKvTfG9jdy8x88z0OHyF3CBkCiqdD1hvdyy6jgDQDngHwC7LGQlSpEBWsyLX3BwAaebgiK0oFFTlla_K9d1Z1o5KukUMih2AbqYJxVnZJPOyfDUsyDokz3voQ-STO6WeJllEp-xihM1M4IznoxAzRf3zckMtWdt7cnvaGfL2-7Lfv6e7z7WP7vEsn5BjSSpd5obU20DRGtAI5j4BDgVCBEG1TasVawRBbJpiiuSzKXFZlwcFoppFtyMMxd3Lj72x8qHvrlek6OZhx9jUCZbTKKdIovT9J5yaWVk_O9tIt9bkS9g_k5mTH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1023295212</pqid></control><display><type>article</type><title>Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Drugeon, H-B ; Rouveix, B ; Michaud-Nerard, A</creator><creatorcontrib>Drugeon, H-B ; Rouveix, B ; Michaud-Nerard, A</creatorcontrib><description>Triclocarban is an antiseptic of the anilide family. Its antibacterial activity was re-assessed in vitro against various susceptible and antibiotic resistant staphylococcus, streptococcus, and enterococcus strains. The results of this study show that, in vitro, the effectiveness of triclocarban antibacterial is maintained at very low MICs ranging from 0.5 to 8 mg/L for the various resistant strains studied. Triclocarban remains still very effective for the treatment of either initially bacterial skin and mucosal infections, or skin and mucosal at risk of super infection.</description><identifier>EISSN: 1769-6690</identifier><identifier>DOI: 10.1016/j.medmal.2012.04.004</identifier><identifier>PMID: 22626523</identifier><language>fre</language><publisher>France</publisher><subject>Anti-Infective Agents, Local - pharmacology ; Carbanilides - pharmacology ; Drug Resistance, Bacterial ; Enterococcus - drug effects ; Microbial Sensitivity Tests ; Staphylococcus - drug effects ; Streptococcus - drug effects</subject><ispartof>Médecine et maladies infectieuses, 2012-06, Vol.42 (6), p.276-279</ispartof><rights>Copyright © 2012. Published by Elsevier SAS.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22626523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drugeon, H-B</creatorcontrib><creatorcontrib>Rouveix, B</creatorcontrib><creatorcontrib>Michaud-Nerard, A</creatorcontrib><title>Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci</title><title>Médecine et maladies infectieuses</title><addtitle>Med Mal Infect</addtitle><description>Triclocarban is an antiseptic of the anilide family. Its antibacterial activity was re-assessed in vitro against various susceptible and antibiotic resistant staphylococcus, streptococcus, and enterococcus strains. The results of this study show that, in vitro, the effectiveness of triclocarban antibacterial is maintained at very low MICs ranging from 0.5 to 8 mg/L for the various resistant strains studied. Triclocarban remains still very effective for the treatment of either initially bacterial skin and mucosal infections, or skin and mucosal at risk of super infection.</description><subject>Anti-Infective Agents, Local - pharmacology</subject><subject>Carbanilides - pharmacology</subject><subject>Drug Resistance, Bacterial</subject><subject>Enterococcus - drug effects</subject><subject>Microbial Sensitivity Tests</subject><subject>Staphylococcus - drug effects</subject><subject>Streptococcus - drug effects</subject><issn>1769-6690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UEtLxDAQDoK46-o_EOnRg60zSZq2R1l8wYKX9SglTVLM0pdJKvTfG9jdy8x88z0OHyF3CBkCiqdD1hvdyy6jgDQDngHwC7LGQlSpEBWsyLX3BwAaebgiK0oFFTlla_K9d1Z1o5KukUMih2AbqYJxVnZJPOyfDUsyDokz3voQ-STO6WeJllEp-xihM1M4IznoxAzRf3zckMtWdt7cnvaGfL2-7Lfv6e7z7WP7vEsn5BjSSpd5obU20DRGtAI5j4BDgVCBEG1TasVawRBbJpiiuSzKXFZlwcFoppFtyMMxd3Lj72x8qHvrlek6OZhx9jUCZbTKKdIovT9J5yaWVk_O9tIt9bkS9g_k5mTH</recordid><startdate>201206</startdate><enddate>201206</enddate><creator>Drugeon, H-B</creator><creator>Rouveix, B</creator><creator>Michaud-Nerard, A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201206</creationdate><title>Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci</title><author>Drugeon, H-B ; Rouveix, B ; Michaud-Nerard, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-9d857ddde0bbe6f6144dde407109066fb8dc3f6311f363c25a785a98740ed3d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2012</creationdate><topic>Anti-Infective Agents, Local - pharmacology</topic><topic>Carbanilides - pharmacology</topic><topic>Drug Resistance, Bacterial</topic><topic>Enterococcus - drug effects</topic><topic>Microbial Sensitivity Tests</topic><topic>Staphylococcus - drug effects</topic><topic>Streptococcus - drug effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Drugeon, H-B</creatorcontrib><creatorcontrib>Rouveix, B</creatorcontrib><creatorcontrib>Michaud-Nerard, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Médecine et maladies infectieuses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drugeon, H-B</au><au>Rouveix, B</au><au>Michaud-Nerard, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci</atitle><jtitle>Médecine et maladies infectieuses</jtitle><addtitle>Med Mal Infect</addtitle><date>2012-06</date><risdate>2012</risdate><volume>42</volume><issue>6</issue><spage>276</spage><epage>279</epage><pages>276-279</pages><eissn>1769-6690</eissn><abstract>Triclocarban is an antiseptic of the anilide family. Its antibacterial activity was re-assessed in vitro against various susceptible and antibiotic resistant staphylococcus, streptococcus, and enterococcus strains. The results of this study show that, in vitro, the effectiveness of triclocarban antibacterial is maintained at very low MICs ranging from 0.5 to 8 mg/L for the various resistant strains studied. Triclocarban remains still very effective for the treatment of either initially bacterial skin and mucosal infections, or skin and mucosal at risk of super infection.</abstract><cop>France</cop><pmid>22626523</pmid><doi>10.1016/j.medmal.2012.04.004</doi><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	EISSN: 1769-6690
ispartof	Médecine et maladies infectieuses, 2012-06, Vol.42 (6), p.276-279
issn	1769-6690
language	fre
recordid	cdi_proquest_miscellaneous_1023295212
source	MEDLINE; Elsevier ScienceDirect Journals Complete
subjects	Anti-Infective Agents, Local - pharmacology Carbanilides - pharmacology Drug Resistance, Bacterial Enterococcus - drug effects Microbial Sensitivity Tests Staphylococcus - drug effects Streptococcus - drug effects
title	Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T10%3A21%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triclocarban%20antibacterial%20activity%20on%20resistant%20staphylococci,%20streptococci,%20and%20enterococci&rft.jtitle=Me%CC%81decine%20et%20maladies%20infectieuses&rft.au=Drugeon,%20H-B&rft.date=2012-06&rft.volume=42&rft.issue=6&rft.spage=276&rft.epage=279&rft.pages=276-279&rft.eissn=1769-6690&rft_id=info:doi/10.1016/j.medmal.2012.04.004&rft_dat=%3Cproquest_pubme%3E1023295212%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1023295212&rft_id=info:pmid/22626523&rfr_iscdi=true